PT  - JOURNAL ARTICLE
AU  - Begoña Bermejo de las Heras
AU  - Javier Cortes Ramon y Cajal
AU  - Elena Galve Calvo
AU  - Juan de la Haba Rodriguez
AU  - Jesus Garcia Mata
AU  - Fernando Moreno Anton
AU  - Ignacio Pelaez Fernandez
AU  - Alvaro Rodriguez-Lescure
AU  - Cesar A Rodriguez Sanchez
AU  - Manuel Ruiz-Borrego
AU  - Edit Remak
AU  - Magdolna Barra
AU  - Maria Rivero
AU  - Javier Soto Alvarez
TI  - The economic burden of metastatic breast cancer in Spain
AID  - 10.1136/ejhpharm-2017-001453
DP  - 2020 Jan 01
TA  - European Journal of Hospital Pharmacy
PG  - 19--24
VI  - 27
IP  - 1
4099  - http://ejhp.bmj.com/content/27/1/19.short
4100  - http://ejhp.bmj.com/content/27/1/19.full
SO  - Eur J Hosp Pharm2020 Jan 01; 27
AB  - Objectives The study aimed to estimate the burden of metastatic breast cancer (mBC) in Spain over 5 years.Methods An incidence-based cost-of-illness model was developed in which a cohort of patients with mBC was followed from the diagnosis of metastatic disease over 5 years or death. Resource use data were collected through a physician survey conducted with 10 clinical experts in Spain. The model distinguished patients according to HER2 and hormonal receptor (HR) status, and followed the patient cohort in monthly cycles.Results The incident cohort was estimated to be 2,923 patients with mBC, consisting of 1,575 HER2−/HR+, 520 HER2+/HR+, 324 HER2+/HR−, and 503 triple negative patients. The estimated mean survival over the 5-year time period was 2.51 years, on average, with longer survival of 3.36 years for HER2+/HR+, 2.41 years for HER2−/HR+, 2.82 years for HER2+/HR− and shortest mean survival of 1.74 years for triple negative patients. The total costs were €469,92,731 for the overall population, €190,079,787 for the HER2-/HR+, €151,045,260 for the HER2+/HR+, €80,827,171 for the HER2+/HR- and €47,540,512 for the triple negative subgroups over 5 years. Per patient total costs were €160,642 on average, €120,664 for HER2-/HR+, €290,346 for HER2+/HR+, €249,152 for HER2+/HR−and €94,572 for triple negative patients over 5 years.Conclusions The economic burden of mBC in Spain is significant, but differs by HER2 and HR status. HER2−/HR +patients account for the highest burden due to the prevalence of this category, but HER2+/HR +patients have the highest per patient costs.